Cartesian Therapeutics, Inc. (RNAC)
10.17
+0.13
(+1.29%)
USD |
NASDAQ |
Aug 24, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics Shareholders Equity (Quarterly) : -125.23M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -125.23M |
| March 31, 2026 | -148.12M |
| December 31, 2025 | -126.24M |
| September 30, 2025 | -35.84M |
| June 30, 2025 | -2.527M |
| March 31, 2025 | -21.79M |
| September 30, 2024 | 0.752M |
| June 30, 2024 | -101.46M |
| March 31, 2024 | -116.80M |
| December 31, 2023 | -143.33M |
| September 30, 2023 | 60.33M |
| June 30, 2023 | 65.45M |
| March 31, 2023 | 74.58M |
| December 31, 2022 | 93.83M |
| September 30, 2022 | 84.91M |
| June 30, 2022 | 89.61M |
| March 31, 2022 | 55.76M |
| December 31, 2021 | 22.52M |
| September 30, 2021 | -18.73M |
| June 30, 2021 | -4.222M |
| March 31, 2021 | -19.57M |
| Date | Value |
|---|---|
| December 31, 2020 | -18.01M |
| September 30, 2020 | -7.382M |
| June 30, 2020 | -13.05M |
| March 31, 2020 | -8.763M |
| December 31, 2019 | 8.397M |
| September 30, 2019 | -4.915M |
| June 30, 2019 | 0.056M |
| March 31, 2019 | 14.82M |
| December 31, 2018 | -5.418M |
| September 30, 2018 | 10.00M |
| June 30, 2018 | 24.26M |
| March 31, 2018 | 41.58M |
| December 31, 2017 | 51.81M |
| September 30, 2017 | 65.08M |
| June 30, 2017 | 78.18M |
| March 31, 2017 | 41.09M |
| December 31, 2016 | 54.96M |
| September 30, 2016 | 65.44M |
| June 30, 2016 | 68.78M |
| March 31, 2016 | 14.03M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Allogene Therapeutics, Inc. | 436.18M |
| Beam Therapeutics, Inc. | 1.067B |
| C4 Therapeutics, Inc. | 247.26M |
| Kyverna Therapeutics, Inc. | 165.55M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 318.63M |
| Total Liabilities (Quarterly) | 443.85M |
| Debt to Equity Ratio | -0.5099 |
| Current Ratio | 7.475 |
| Net Debt Paydown Yield | -3.18% |